Literature DB >> 7263111

Chlorpropamide bioavailability and pharmacokinetics.

R Huupponen, R Lammintausta.   

Abstract

The pharmacokinetics of chlorproamide was studied in eight healthy volunteers after intravenous and oral dosage. A long elimination half-life with considerable variations between subjects was recorded. The normalized areas under the curve were in close agreement between the subjects, suggesting that they had all absorbed the same magnitude of chlorpropamide. The AUCs after i.v. and p.o. administration did not differ significantly from each other. Thus, the differences in the bioavailability do not seem to be a critical factor in the previously reported large interindividual variations in chlorpropamide steady-state concentrations.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7263111

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  4 in total

1.  The relationship between debrisoquine oxidation phenotype and the pharmacokinetics of chlorpropamide.

Authors:  J Kallio; R Huupponen; K Pyykkö
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis.

Authors:  Sheila Annie Peters
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

3.  Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination.

Authors:  P J Neuvonen; S Kärkkäinen; R Lehtovaara
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.

Authors:  Ji-Hong Shon; Young-Ran Yoon; Min-Jung Kim; Kyoung-Ah Kim; Young-Chae Lim; Kwang-Hyeon Liu; Dong-Hoon Shin; Chung Han Lee; In-June Cha; Jae-Gook Shin
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.